Medicine Ahead
What medicine can do now.What may come next.
Explore treatments, understand the evidence, and follow what’s in development.
Primary sources linked. Study populations, methods and limitations included. Our editorial standards
Featured research · EloraTZPMore weight loss.
More weight loss.
More treatment stops.
Adding eloralintide to tirzepatide improved weight loss in a phase 2 trial in adults with type 2 diabetes. More participants stopped because of side effects.
EloraTZPEloralintide 9 mg + tirzepatide 15 mg23.3%
TirzepatideTirzepatide 15 mg14.8%
Modeled estimates assume continued treatment for 48 weeks. Confidence intervals were not supplied in the announcement.
Stopped because of side effects
EloraTZP27.0%
Tirzepatide2.9%
Trial context & sources
367 randomized across all trial arms; overweight or obesity with type 2 diabetes. Weekly doses, given as separate injections. The tirzepatide comparison was secondary; placebo was the primary comparison.
Sponsor report · Sep 30, 2026EASD results & safety tables